PA
ESPR

Profund Advisors’s Esperion Therapeutics ESPR Stock Holding History

Profund Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$271K Sell
85,881
-4,563
-5% -$12.8K 0.01% 875
2026
Q1 		$248K Buy
90,444
+20,732
+30% +$65.6K 0.01% 883
2025
Q4 		$258K Buy
69,712
+27,524
+65% +$88.9K 0.01% 989
2025
Q3 		$112K Buy
+42,188
New +$81.6K ﹤0.01% 1023
2025
Q2 		– Sell
-51,113
Closed -$73.6K – 1011
2025
Q1 		$73.6K Buy
51,113
+5,429
+12% +$10K ﹤0.01% 969
2024
Q4 		$101K Buy
+45,684
New +$107K ﹤0.01% 1069
2023
Q2 		– Sell
-30,581
Closed -$48.6K – 1093
2023
Q1 		$48.6K Buy
+30,581
New +$158K ﹤0.01% 1082

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Profund Advisors's ESPR Position: Q2 2026 in Review

Profund Advisors reduced its Esperion Therapeutics (ESPR) stake by 5% in Q2 2026, selling an estimated $12.8K and leaving 85,881 shares worth $271K. The position accounts for 0.01% of the portfolio, ranked #875.

Profund Advisors first reported a position in ESPR in Q1 2023 and has held it in 7 quarters since. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Profund Advisors held 85,881 shares of Esperion Therapeutics worth $271K as of Q2 2026.
  • Profund Advisors sold 4,563 Esperion Therapeutics shares in Q2 2026, an estimated $12.8K.
  • Esperion Therapeutics made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #875 holding.
  • Profund Advisors first reported a position in Esperion Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.